Prof Baselga talks to ecancer at ESMO 2012 in Vienna about his future role at Memorial Sloan-Kettering Cancer Centre, it's new phase 1 programme, and the future of personalised medicine.

Focussing on non-responders to cancer therapy and learning from out liers how respond the best to new therapies.

Prof Baselga covers improved sharing of clinical trial data, assessing mutations, curiosity driven research and how next generation sequencing is set to take off in the next 2 years.

 Filming supported by Caris Life Sciences